Chinese regulators have reportedly cleared a plan by billionaire Jack Ma’s Ant Group Co. to raise 10.5 billion yuan ($1.5 billion) for its consumer unit.
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.53) by 3.77 percent. This is a 37.5 percent decrease over losses of $(0.40) per
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the Company has entered into